Does Medicare Cover Mounjaro?

Eli Lilly did something interesting with tirzepatide. They got the FDA to approve it twice, under two different brand names, for two different uses. Mounjaro was first — type 2 diabetes, mid-2022. Zepbound came roughly 18 months later — chronic weight management, late 2023. Same active molecule. Same syringe and dose. Different cardboard box, different label, and as it happens, completely different relationship with Medicare.

This is the cleanest example in modern medicine of how an FDA label, not a chemistry, determines what Medicare will pay for. So if you’re asking about Mounjaro coverage, the first thing to nail down is which prescription you actually have — because Mounjaro and Zepbound look like cousins but Medicare treats them like strangers.

Mounjaro is covered. Zepbound isn’t.

That’s the single most important sentence on this page.

If your doctor prescribes Mounjaro for type 2 diabetes, your Medicare Part D plan will almost certainly cover it. It’s on the formulary of every major standalone PDP and most Medicare Advantage plans with drug coverage, almost always on Tier 3 (preferred brand). Prior authorization is common but generally approved when your records support a type 2 diabetes diagnosis.

If your doctor prescribes Zepbound for weight loss, Medicare will not pay for it. Period. The drug falls within the long-standing federal exclusion of anti-obesity medications from Part D. The cash price is in the $1,000-per-month neighborhood, and there’s no manufacturer copay assistance available to Medicare beneficiaries.

This is why two patients on the same medication, in the same doses, with the same prescriber, can be paying $40 versus $1,000 a month. The difference is what’s printed on the box.

Why Mounjaro coverage is straightforward in 2026

For diabetics, Mounjaro is one of the easier prescriptions to navigate on Medicare:

• It’s on Tier 3 of nearly every formulary.
• Prior authorization is required by most plans, but the approval criteria are well-defined and documented A1c results plus a type 2 diabetes diagnosis are usually sufficient.
• Step therapy — meaning you have to try Metformin or another oral first — is common but most patients have already tried Metformin before being moved to a GLP-1, so the requirement is more bureaucratic than substantive.
• The new $2,000 annual cap on Part D out-of-pocket spending means even a year of full-price Mounjaro copays can’t exceed $2,000.

For a typical Medicare diabetic on Mounjaro plus, say, Metformin and a statin and an ACE inhibitor, the monthly cost picture in 2026 looks something like this: $590 deductible burned through fast (one Mounjaro fill almost gets you there), then $40–$100 copays for a few months, then $0 for the rest of the year after hitting the $2,000 cap.

This is meaningfully better than it was in 2024 and earlier, when there was no out-of-pocket cap and the catastrophic phase still required 5% coinsurance. The 2025 redesign capped your true exposure, which makes Mounjaro reasonable on a fixed income for the first time.

The Zepbound problem

The exact same molecule, packaged for weight loss, costs roughly the same amount but isn’t covered. Patients without diabetes who would benefit from tirzepatide for weight management run into a familiar wall: pay cash, find an alternative, or wait.

Some have tried to get Zepbound prescribed off-label as Mounjaro for diabetes. This doesn’t work. Plans aren’t fooled by it; the diagnosis code on the claim is checked against the ICD-10 record, and prescribers risk fraud exposure if they intentionally miscode prescriptions to get coverage.

The legitimate workaround is the cardiovascular indication path that Wegovy opened in 2024. Eli Lilly is running outcomes studies on Zepbound for cardiovascular risk reduction. If those trials show benefit and Lilly secures a CV indication, expect a CMS coverage update to follow — though no specific timeline is public yet.

Real-world cost scenarios

Two scenarios bring the cost picture into focus.

Diabetic, Medicare Advantage with drug coverage Mounjaro on Tier 3 of a popular MA plan in 2026. Plan deductible is $590. First fill: pay cash price (around $700) until deductible is met. Months 2 through roughly 5: $50 copay per month. By the time monthly copays plus the deductible add up to $2,000 — usually around month 5 or 6 — you’ve hit the catastrophic threshold and pay $0 for the rest of the year. Annual out-of-pocket: $2,000.

Non-diabetic, prescribed Zepbound for weight management No coverage. Pay cash. Cash price runs roughly $1,000–$1,100 per month. Annual out-of-pocket: ~$12,000. This is the scenario where most patients walk away.

Diabetic on Mounjaro plus other Tier 3+ drugs This is common — diabetics often take Mounjaro plus insulin plus a statin plus an ACE inhibitor. The combined out-of-pocket adds up faster, but the cap stays at $2,000 regardless.

Side-effect-driven discontinuation matters more on Medicare

A practical consideration: GLP-1 drugs like Mounjaro have meaningful side effects, particularly gastrointestinal issues, in the first weeks of treatment. About 15–20% of patients in clinical trials discontinue due to nausea or other GI symptoms.

On commercial insurance, you can switch drugs and the prior auth can be re-run quickly. On Medicare, switching from Mounjaro to Ozempic to Trulicity all triggers fresh prior authorizations, and step therapy rules sometimes require you to fail Mounjaro for a documented period before a different GLP-1 can be authorized. Build in that timeline if your initial Mounjaro experience isn’t going well.

A practical tip: ask your prescriber to start at the lowest dose (2.5 mg) and titrate slowly. The clinical trials suggest GI side effects are dose-dependent, and patients who escalate slowly are more likely to stay on therapy. This is good clinical practice anyway, but it’s especially important when the bureaucratic cost of switching is high.

How to confirm Mounjaro coverage on your plan

Three concrete steps:

1. Check your formulary. On medicare.gov/plan-compare or your carrier’s site, search for “tirzepatide” or “Mounjaro.” Confirm it’s listed and note the tier, prior authorization flag, and step therapy flag.
2. Verify your diagnosis is documented. Pull your most recent A1c result or ask your doctor’s office to confirm the type 2 diabetes diagnosis is in your chart with appropriate ICD-10 coding (E11.x).
3. Submit the prior authorization before the first fill. Don’t show up at the pharmacy and hope. Have the prescriber’s office submit and confirm approval first; the alternative is paying cash on the first visit while you wait for retroactive approval.

If your Medicare plan denies Mounjaro for type 2 diabetes despite a clear diagnosis, the appeal path is real and frequently successful. Submit a redetermination with chart notes and lab results attached.

Bottom line

Mounjaro for type 2 diabetes is one of the smoother GLP-1 coverage stories on Medicare in 2026. Zepbound for weight loss continues to be one of the most painful coverage gaps in the system. Same drug. Different label. The whole thing turns on whether the prescription you’ve been handed is for the diabetes brand or the weight-loss brand — so check that detail before you fill.